Since 1989, Dr. Richard Conklin has grown his oncology/hematology practice as the first full-time oncologist in Aberdeen. The current Cancer Center was remodeled in 1996, and again in 2006, to better accommodate patients, provide space for the latest available treatments and allow for the implementation of an electronic medical records system. In 2003 a Varian 21EX linear accelerator, which can also perform specialized treatments such as Intensity Modulated Radiation Therapy (IMRT), replaced the original linear accelerator from 1988.
As the population of Aberdeen continues to grow and our baby boomers enter the Medicare ranks, Avera St. Luke’s and Dr. Conklin see the need to accommodate projected increases in cancer incidence. The new partnership was a natural, and a new day of cancer care for Aberdeen is at the forefront.
Avera St. Luke’s, Dr. Conklin and the experienced team at Avera Medical Group Oncology and Hematology Aberdeen bring new opportunities for a coordinated, comprehensive care model that will meet challenges in cancer care for years to come. The Avera Cancer Institute will greatly benefit our patients and their families by enhancing the ability to triumph over these personal challenges.
- Currently more than 17,000 patient visits each year
- More than 8,000 infusion treatments annually
- Projecting a 67% increase in cancer incidence in older adults nationwide over the next 20 years
- 84% of our patients come from Aberdeen and the surrounding seven counties
- Percent of population over age 65 in Brown and adjoining counties is 22%, well above the national average of 14
NCCTG N093B: Phase I/II study of Panobinostat (LBH589) and Letrozole in patients with triple negative metastatic breast cancer
NSABP B-49: A phase III clinical trial comparing the combination of Docetaxel plus Cyclophosphamide to nthracycline-based chemotherapy regimens for women with node-positive or high-risk node-negative, HER2-negative breast cancer
NSABP B-47: A randomized phase III trial of Adjuvant therapy comparing chemotherapy alone (six cycles of Docetaxel plus Cyclophosphamide or four cycles of Doxorubicin plus Cyclophosphamide followed by weekly Paclitaxel) to chemotherapy plus Trastuzumab in women with node-positive or high-risk node-negative ER2-low invasive breast cancer
NSABP B-43: A phase III clinical trial comparing Trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER2-neu positive ductal carcinoma in situ resected by lumpectomy
SWOG S1007: A phase III clinical trial of standard Adjuvant EndocrineTherapy +/- chemotherapy in patients with one to three positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less
Alliance A221102: Randomized double-blind placebo controlled study of subcutaneous testosterone in the Adjuvant treatment of postmenopausal women with Aromatase inhibitor induced Arthralgias
ECOG E3A06: Randomized phase III trial of Lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma
ECOG E1505: A phase III randomized trial of Adjuvant chemotherapy with or without Bevacizumab for patients with completely resected stage IB (≥ 4 cm) – IIIA non-small cell lung cancer (NSCLC)
ECOG E5508: Randomized phase III study of maintenance therapy with Bevacizumab, Pemetrexed, or a combination of Bevacizumab and Pemetrexed following Carboplatin, Paclitaxel and Bevacizumab for advanced non-squamous NSCLC
Alliance A221101: The use of Armodafinil (Nuvigil) to reduce cancerrelated fatigue in patients with glioblastoma multiform
NSABP P-5: Statin polyp prevention trial in patients with resected colon cancer
CALGB C80702: A phase III trial of six versus 12 treatments of Adjuvant FOLFOX plus Celecoxib or placebo for patients with resected stage III colon cancer
SWOG S0931: “EVEREST”: EVErolimus for renal cancer ensuing surgical therapy, a phase III study
Amgen 20070782: A randomized, double-blind, placebo-controlled study to evaluate the long-term safety and efficacy of Darbepoetin Alfa Administered at 500 ug once every three weeks in anemic subjects with advanced stage non-small cell lung cancer receiving multi-cycle chemotherapy
Amgen 20090482: A randomized, doube-blind, multicenter study of Denosumab compared with Zoledronic Acid (Zometa) in the treatment of bone disease in subjects with newly diagnosed multiple myeloma
Genoptix: Clinical evaluation of Next Generation Sequencing (NGS) for the diagnosis and management of myelodysplastic syndrome (MDS)